AHMEDABAD: Healthcare major, Zydus Cadila has filed IND (Investigational New Drug) application for anti-diabetic and anti-obesity drug with Drugs
Controller General of India (DCGI). The drug (ZYD1) designed and developed by Zydus Research Centre is a novel candidate in the class of anti-diabetic agents known as incretin mimetics and has displayed a better efficacy and safety profile. According to the company, the anti-diabetic drug agent (incretin mimetics) is poised to dominate the future of anti-diabetic therapy and presents a huge opportunity in bridging the un-met medical needs that still continues to dodge the treatment and care of diabetes. The new class of drugs called incretins came to the fore in May 2005. ZYD1 has demonstrated beneficial effects in preclinical animal models on glucose reduction and added benefits of weight loss. During the preclinical studies, the new drug displayed a differentiated preclinical safety profile with no nausea-like symptoms and absence of antibody generation. Commenting on the development, Pankaj Patel, Chairman and Managing Director, Zydus Cadila, said, “This discovery is an important achievement for us. We believe that it holds promising commercial potential as a best-in-class candidate due to un-met medical needs in the treatment of diabetes.” The number of diabetics in the world, now estimated to be 246 million and is expected to increase rapidly to 380 million in 2025. Currently 41 million (16.6%) of the diabetic population lives in India and it is expected to rise to 70 million (18.4%) by 2025. In 2025 nearly half of the world’s diabetic population will be from India, China, Brazil, Russia and Turkey. The global anti-diabetic market was estimated at $24 bn in 2008.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment